N
RIGL icon

Natixis’s Rigel Pharmaceuticals RIGL Stock Holding History

Natixis’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.2K Buy
+1,591
New +$49.1K ﹤0.01% 1017
2024
Q2 		– Sell
-3,000
Closed -$44.4K – 1122
2024
Q1 		$44.4K Sell
3,000
-750
-20% -$10.1K ﹤0.01% 830
2023
Q4 		$54.4K Hold
3,750
– – ﹤0.01% 816
2023
Q3 		$40.5K Sell
3,750
-1,975
-34% -$23.8K ﹤0.01% 838
2023
Q2 		$73.8K Buy
+5,725
New +$77.4K ﹤0.01% 815

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis's RIGL Position: Q2 2026 in Review

Natixis opened a new position in Rigel Pharmaceuticals (RIGL) in Q2 2026: 1,591 shares worth $62.2K. The stake represents ﹤0.01% of the portfolio and ranks #1017 among its holdings. This is a return to the name: Natixis previously reported a position in RIGL as recently as Q1 2024.

Natixis first reported a position in RIGL in Q2 2023 and has held it in 5 quarters since. The position peaked at $73.8K in Q2 2023. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Natixis held 1,591 shares of Rigel Pharmaceuticals worth $62.2K as of Q2 2026.
  • Rigel Pharmaceuticals was a new Natixis position in Q2 2026.
  • Rigel Pharmaceuticals made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #1017 holding.
  • Natixis first reported a position in Rigel Pharmaceuticals in Q2 2023 and has held it in 5 quarters since.
  • Natixis's Rigel Pharmaceuticals position peaked at $73.8K in Q2 2023.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.